Kardi Ai raises €5.3M Series A for predictive heart monitoring
Czech medtech startup Kardi Ai has secured €5.3 million in a round led by Callisto Health to expand its long-term ECG monitoring across Europe and Asia.
SUMO· the number puzzle
Dialo· learn languages by speaking
ediviewer· read EDI files like documents
giftdetect· the right gift in minutesCzech medtech startup Kardi Ai has raised €5.3 million in a Series A round led by German HealthTech fund Callisto Health. Česká spořitelna and Slovenská sporiteľňa joined through Seed Starter, alongside BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels.
The company builds a platform for long-term heart rhythm monitoring and early detection of possible rhythm disorders. It combines a fitness chest strap with an ECG sensor, a mobile app and AI-powered analysis of the recordings. Kardi Ai says the system does not issue diagnoses; it supports clinical decisions by giving physicians data collected over longer periods.
Why long-term monitoring matters
Conventional cardiac examinations capture heart activity only for a limited time and can miss irregularities that come and go. Kardi Ai lets patients record their rhythm during everyday activities, helping doctors judge whether further care is needed.
In the Czech Republic the company works with more than 70 hospitals and over 20 corporate and employee-benefit partners, and its technology is used by more than 6,000 people. According to the company, the system flagged possible arrhythmias in about a quarter of users, including more than 500 findings classed as critical. It entered Slovakia several months ago and works there with more than 20 physicians, mainly cardiologists.
Expansion and predictive models
Kardi Ai is also active in Poland, Romania and Bulgaria and is preparing to enter Germany once pilot projects finish. It has secured regulatory approvals supporting its planned move into India and the United Arab Emirates, and is completing medical device approval in Singapore.
The new money will fund this push across Europe and Asia, with Germany a near-term priority. The company also plans predictive models that analyse multiple ECG measurements to estimate arrhythmia risk before it occurs. These models are still in development and need clinical validation and regulatory approval before use in medical practice.
"Nearly two billion people live in the markets where we already operate or are preparing to launch," said co-founder and CEO Vlastimil Hrabal, adding that the capital will help validate the technology at global scale and across patient demographics.
Apps worth a look
SUMO: the number puzzleTap the right tiles, add them up, hit the target. Easy to learn, hard to master. Free, for all ages.
Dialo: learn languages by speakingTalk to an AI conversation partner; every sentence comes back corrected and explained in your language. 9 languages, A1 to C2.
ediviewer: read EDI files like documentsOpen EDIFACT and X12 messages, see every segment explained, convert to JSON/XML, export PDF and Excel. Runs locally, no upload.
giftdetect: the right gift in minutesPick who it is for, the occasion and their personality. The search engine reads product descriptions from local shops and ranks what fits. Free, no sign-up.
